Brian Powl - 13 Nov 2025 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Role
Chief Commercial Officer
Signature
Teresa Bair, Attorney-in-fact for Brian Powl
Issuer symbol
KURA
Transactions as of
13 Nov 2025
Transactions value $
-$99,329
Form type
4
Filing time
14 Nov 2025, 20:00:08 UTC
Previous filing
29 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Powl Brian T. Chief Commercial Officer C/O KURA ONCOLOGY, INC., 4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO Teresa Bair, Attorney-in-fact for Brian Powl 14 Nov 2025 0001934232

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KURA Common Stock Award $0 +48.9K +49.06% $0.00 149K 13 Nov 2025 Direct F1
transaction KURA Common Stock Sale -$99.3K -8.89K -5.98% $11.18 140K 14 Nov 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of Restricted Stock Units (RSUs). The RSUs vest 50% immediately and 50% on 11/13/26.
F2 Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 11/13/25.